(Q41632994)

5 October 2017

1 reference

title

Taming TNF: strategies to restrain this proinflammatory cytokine (English)

1 reference

5 October 2017

0 references

Eigler A

1

1 reference

5 October 2017

Sinha B

series ordinal

2

1 reference

5 October 2017

Hartmann G

series ordinal

3

1 reference

5 October 2017

Endres S

series ordinal

4

1 reference

5 October 2017

1 October 1997

1 reference

5 October 2017

1 reference

5 October 2017

18

1 reference

5 October 2017

487-492

1 reference

5 October 2017

10

1 reference

Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin

5 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Molecular cloning of the complementary DNA for human tumor necrosis factor.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Cachectin and tumour necrosis factor as two sides of the same biological coin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Structure of tumour necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

The tumor necrosis factor ligand and receptor families.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

A human inhibitor of tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Cytokine-binding proteins: stimulating antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Tumor necrosis factor induces rapid production of 1'2'diacylglycerol by a phosphatidylcholine-specific phospholipase C.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Effects of recombinant tumour necrosis factor (rTNF-alpha) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF-alpha administration in isolated limb perfusions in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Cytokines and gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Receptor-mediated label-transfer assay (RELAY): a novel method for the detection of plasma tumor necrosis factor at attomolar concentrations.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

The pathophysiology of tumor necrosis factors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Anticytokine strategies in the treatment of the systemic inflammatory response syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Tumor necrosis factor: a pleiotropic cytokine and therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Function and activation of NF-kappa B in the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

I kappa B: a specific inhibitor of the NF-kappa B transcription factor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Phosphodiesterase inhibitors: new opportunities for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Effects of rolipram on responses to acute and chronic antigen exposure in monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Detection of plasma tumor necrosis factor, interleukins 6, and 8 during the Jarisch-Herxheimer Reaction of relapsing fever

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Tumor necrosis factor and the Jarisch-Herxheimer reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Tumor-necrosis factor and other cytokines in cerebral malaria: experimental and clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Tumor necrosis factor and disease severity in children with falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Detection of endogenous cytokines in sera or in lymph nodes obtained from patients with sarcoidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Raised serum levels of cachectin/tumor necrosis factor alpha in renal allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Tumor Necrosis Factor Levels in Serum and Bronchoalveolar Lavage Fluid of Patients with the Adult Respiratory Distress Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Plasma levels of tumor necrosis factor in the adult respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Circulating tumour necrosis factor-alpha (cachectin) in myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Production of tumor necrosis factor alpha and hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Suppression of tumor necrosis factor-α production by interleukin-10 is enhanced by cAMP-elevating agents

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Inhibition of cytokine production by cyclosporin A and transforming growth factor beta

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Ciliary neurotrophic factor inhibits brain and peripheral tumor necrosis factor production and, when coadministered with its soluble receptor, protects mice from lipopolysaccharide toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Prostacyclin analogs suppress the synthesis of tumor necrosis factor-alpha in LPS-stimulated human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Histamine suppresses gene expression and synthesis of tumor necrosis factor alpha via histamine H2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

The protective role of endogenously synthesized nitric oxide in staphylococcal enterotoxin B-induced shock in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Inhibition by all-trans-retinoic acid of tumor necrosis factor and nitric oxide production by peritoneal macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Cyclosporine A inhibits TNF production without decreasing TNF mRNA levels

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Monoclonal antibody to TNF in severe septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

Anticytokine therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901118-3

7 January 2021

10.1016/S0167-5699(97)01118-3

Identifiers

DOI

1 reference

5 October 2017

1 reference